New weight loss drugs called GLP-1 agonists, initially approved for type 2 diabetes, are effective in combatting obesity. However, their high cost and limited Medicaid coverage obstruct accessibility and affordability. Medicaid coverage varies by state, with some states considering expansion. Medicaid utilization and spending on these drugs have increased significantly since 2019. Expanding Medicaid coverage could improve access and potentially reduce obesity-related chronic disease rates, but could also increase utilization and spending.
Verily Faces Lawsuit Over Alleged HIPAA Violations
John Blacksmith reports: Verily, owned by Alphabet, is facing a lawsuit filed by an ex-employee who alleges the misuse of the personally identifiable health information
